| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/22/2009 | WO2009063241A1 3-hydroxyanthranilic acid or salts thereof1 for treating cancer or infections |
| 05/22/2009 | WO2009063215A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009063202A2 Use of crth2 antagonist compounds |
| 05/22/2009 | WO2009062391A1 Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia |
| 05/22/2009 | WO2009029836A3 Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes |
| 05/22/2009 | WO2009019505A3 Drug combinations for the treatment of duchenne muscular dystrophy |
| 05/22/2009 | WO2009016072A3 A morpholinyl anthracycline derivative combined with protein kinase inhibitors |
| 05/22/2009 | WO2008100450A3 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 05/22/2009 | WO2008100449A3 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 05/22/2009 | CA2705708A1 Methods for treating obesity and obesity related diseases and disorders |
| 05/22/2009 | CA2705370A1 Heteroaryloxy quinazoline derivatives |
| 05/21/2009 | US20090131946 Devices and Methods for the Restoration of a Spinal Disc |
| 05/21/2009 | US20090131890 Protease inhibitors in absorbent articles |
| 05/21/2009 | US20090131404 Combinations |
| 05/21/2009 | US20090131382 Treatment of rheumatoid arthritis using imatinib |
| 05/21/2009 | US20090131340 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations |
| 05/21/2009 | US20090130695 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130676 Interaction trap systems for detecting protein interactions |
| 05/21/2009 | US20090130122 Methods for treating rheumatoid arthritis using IL-17 antagonists |
| 05/21/2009 | US20090130095 Composition comprising tumor necrosis factor (CD40) specific immunoglobulin for treatment and prevention of autoimmune diseases |
| 05/21/2009 | US20090130080 Reducing blood glucose level in a non-obese or obese human afflicted with Type 2 diabetes by administering purified human placental alkaline phosphatase |
| 05/21/2009 | US20090130078 Treatment for Cardiovascular Disease |
| 05/21/2009 | US20090130063 Process for separating and determining the viral load in a pancreatin sample |
| 05/20/2009 | EP2060272A2 Vitamin-mitomycin conjugates |
| 05/20/2009 | EP2060270A2 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 05/20/2009 | EP2060268A1 Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| 05/20/2009 | EP2059260A2 Pharmaceutical compositions comprising hgh for oral delivery |
| 05/20/2009 | EP2059259A1 Pharmaceutical compositions for the treatment of fungal infections |
| 05/20/2009 | EP2059254A1 Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| 05/20/2009 | EP2059246A2 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor |
| 05/20/2009 | EP1883302A4 Jak kinase inhibitors and their uses |
| 05/20/2009 | EP1414451B1 Opioid agonist formulations with releasable and sequestered antagonist |
| 05/20/2009 | EP1231910B1 Pentamidine for treating cancer |
| 05/20/2009 | CN101437577A Combination therapy for diseases involving angiogenesis |
| 05/20/2009 | CN101437543A Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases |
| 05/20/2009 | CN101437542A Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| 05/20/2009 | CN101437501A Prolongation of survival of an allograft by inhibiting complement activity |
| 05/20/2009 | CN101437489A Homeopathic composition and kit therefore |
| 05/20/2009 | CN101433722A Fusions of cytokines and tumor targeting proteins |
| 05/20/2009 | CN101433717A Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients |
| 05/20/2009 | CN101433716A Composition for treating malignant solid tumors and preparation thereof and use |
| 05/20/2009 | CN101433535A Novel sensitive enhancement and synergistic substance for chemical treatment of tumor |
| 05/20/2009 | CN101433520A Anticancer sustained-release agent containing epothilone |
| 05/20/2009 | CN100489654C Laser projector |
| 05/20/2009 | CN100488984C Reducing immunogenicity of fusion proteins |
| 05/20/2009 | CN100488576C Intelligent cerebrospinal fluid displacement instrument |
| 05/20/2009 | CN100488568C Cell preparation capable of excreting chalone of endothelium, and application for preparing medicine for treating tumor |
| 05/20/2009 | CN100488564C Preventives/remedies for snore or respiratory disturbances during sleep |
| 05/20/2009 | CN100488563C Modified anti-EGFR antibody with reduced immunogenicity |
| 05/20/2009 | CN100488512C Compositions for treatment of cell proliferative disorders and its uses |
| 05/20/2009 | CN100488511C Compound and use for preparation of the medicament for treatment of benign prostatic hyperplasia and relative diseases |
| 05/20/2009 | CN100488502C Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 05/20/2009 | CN100488500C Use of COX-2 inhibitors for preventing immunodeficiency |
| 05/20/2009 | CN100488497C Use of leukotriene in preparing medicament |
| 05/19/2009 | US7534859 Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse |
| 05/19/2009 | US7534773 reduces the expression of testosterone-repressed prostate message-2 provides therapeutic benefits in the treatment of cancer for example prostate cancer and renal cell cancer; Combined use with taxanes synergistically enhances cytotoxic chemosensitivity of androgen-independent prostate cancer |
| 05/19/2009 | US7534772 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 05/19/2009 | US7534768 Synergistic combination of loop diuretic and cardiac glycoside; impregnated intraocular/contact lens |
| 05/19/2009 | US7534593 Crystals of glucokinase and methods of growing them |
| 05/19/2009 | US7534450 Promoting metallothioneins by administering a copper-free nutrient supplement containing 50 - 150 mg of zinc, and further containing vitamin B6, pyridoxal-5'-phosphate, vitamin E, vitamin A, vitamin C, selenium, glutathione, taurine, and a mixture of amino acids |
| 05/19/2009 | US7534443 Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient |
| 05/19/2009 | US7534438 Reducing viscosity, cohesion; mixture containing thioreodxin; cystic fibrosis |
| 05/19/2009 | US7534430 Administering monoclonal or polyclonal antibody to treat multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease |
| 05/19/2009 | US7534425 As well as Paget's disease, neurological/neuromuscular diseases, nerve diseases, and/or psychotropic diseases; chloride channel modulators |
| 05/19/2009 | US7534240 Negative pressure wound therapy system with provision for introduction of an agent |
| 05/19/2009 | CA2505990C Palonosetron for the treatment of chemotherapy-induced emesis |
| 05/19/2009 | CA2407929C Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist |
| 05/19/2009 | CA2400784C Therapeutic product, use and formulation thereof |
| 05/19/2009 | CA2388728C Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |
| 05/19/2009 | CA2387247C Use of neutralizing agents to growth factors for reducing wound scarring |
| 05/19/2009 | CA2382580C Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| 05/19/2009 | CA2367955C Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/19/2009 | CA2352564C Use of effectors of the central cholinergic nervous system |
| 05/19/2009 | CA2338651C Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity |
| 05/14/2009 | WO2009061786A2 Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists |
| 05/14/2009 | WO2009061721A1 Complement c1q inhibitors for the prevention and treatment of glaucoma |
| 05/14/2009 | WO2009061445A2 Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction |
| 05/14/2009 | WO2009060218A1 Novel complexes and a process for their preparation |
| 05/14/2009 | WO2009060073A1 Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates |
| 05/14/2009 | WO2009059425A1 Stat3 inhibitors for the treatment of fibrosis |
| 05/14/2009 | WO2009023333A3 Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines |
| 05/14/2009 | WO2008041236A3 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 05/14/2009 | WO2005115469A3 Estrogen modulation of ifn-gamma-mediated conditions and diseases |
| 05/14/2009 | US20090124684 Stimulation Of CPT-1 As A Means To Reduce Weight |
| 05/14/2009 | US20090124658 Treatments for Viral Infections |
| 05/14/2009 | US20090124552 Methods and Compositions for Regenerating Connective Tissue |
| 05/14/2009 | US20090123938 Contacting a candidate antagonist with a MCP-1 receptor polypeptide having an amino acid sequence at least 95% homologous to an extracellular domain of a specific sequence, and comparing the binding of MCP-1 to the receptor polypeptide; decreased binding indicates an antagonist |
| 05/14/2009 | US20090123565 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 05/14/2009 | US20090123547 Methods and Compositions for Regenerating Connective Tissue |
| 05/14/2009 | US20090123542 oral administered powder mixture comprising a dissolved whey protein to increase release the bioactive carotenoid, polyphenol, vitamins, flavonoid, isoflavone, ceramide |
| 05/14/2009 | US20090123530 Liposome Drug Delivery |
| 05/14/2009 | US20090123511 Biomaterial derived from vertebrate liver tissue |
| 05/14/2009 | US20090123503 Conditioned Cell Culture Medium Compositions and Methods of Use |
| 05/14/2009 | US20090123460 Immunostimulatory combinations |
| 05/14/2009 | US20090123455 Slimming cosmetic composition containing a substance inducing the production of il-6 |
| 05/14/2009 | US20090123437 Methods for collecting and using placenta cord blood stem cells |
| 05/14/2009 | US20090123435 Cultured three-dimensional tissues and uses thereof |
| 05/14/2009 | US20090123422 Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y |
| 05/14/2009 | US20090123420 Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase |